My current work is research into the selection of neoantigens sufficient to create and immune response against cancer cells via mRNA vaccination. This work combines my expertise in tumor sequencing and molecular assay design as well as developing novel pieplines and workflows. My most recent first author publications have been in the field of epilepsy and seizure disorders in general with additional work in cancer. Primarily using whole exome sequencing to find both causative and actionable variants in seizure and cancer patient populations. The main thrust of this work has been utilizing RNA profiling to look at the functional causes and effects of seizures on the brain. My most current work and publications have been focused on the development of clinical testing for the SARS-CoV-2 pandemic, immune response to vaccination and biomarkers predictive of severe disease risk in patients with COVID. Additionally, My earlier work was in the genetics of lung function as it relates to the physiology of lung disease and hypertension.